In a new job - March 29, 2022
He is the new CEO of Exact Therapeutics
EXACT Therapeutics has announced that its Board of Directors has appointed Per Walday as Chief Executive Officer. Per Walday has experience from research to commercialization of therapeutics and medical devices globally, including drug-device combination within the field of oncology. “The Board and I are very excited to welcome Per as CEO of EXACT-Tx. He brings […]
Collaboration - January 20, 2021
Exact Therapeutics collaborates with GE Healthcare
Exact Therapeutics has announced a collaboration with GE Healthcare to develop an ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT) across multiple disease conditions. “We are delighted to collaborate with GE Healthcare, a leader in the field of diagnostic imaging and ultrasound. We look forward to working closely with GE […]
Clinical Trials - September 8, 2020
Exact Therapeutics restarts Phase I study
Exact Therapeutics has announced that the phase I ACTIVATE study evaluating ACT in patients with metastatic colorectal cancer has enrolled the first patient following temporary suspension due to the COVID-19 pandemic. To date six patients have now been enrolled in the study being led by Professor Udai Banerji at the Royal Marsden Hospital (RMH) in […]
Financing - July 31, 2020
Exact Therapeutics raises 155 million NOK and lists on Oslo Stock Exchange’s Merkur Market
Exact Therapeutics announces that its shares have been admitted to trading on Oslo Stock Exchange’s Merkur Market under the ticker EXTX-ME with first day of trading 14 July 2020, following the successful completion of a NOK 155 million private placement. Following a bookbuilding period from 4 – 16 June 2020, the company has raised NOK […]
